ECDC is following reports from several European Union and European Economic Area (EU/EEA) countries of substantial increases in the detection of parvovirus B19 (B19V).
ECDC, DG SANTE and EFSA, supported by a consortium composed of Epiconcept and Integrated Quality Laboratory Services (IQLS), jointly carried out a country visit to Kosovo* from 9 to 13 October 2023, which is part of ECDC’s accession support activities to contribute to the advancement of a One Health approach against antimicrobial resistance (AMR) in the Western Balkans.
Diverse groups of experts helped assess the relationships between drivers on an extended time-horizon: assessing either no connection, some connection or a strong connection between two drivers along any of their possible future trajectories.
This global technical consultation report brings together viewpoints from experts spanning a range of disciplines with the key objective of seeking consensus regarding the terminology used to describe the transmission of pathogens through the air that can potentially cause infection in humans.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
Since the beginning of 2024, and as of 3 April, no MERS-CoV cases have been reported by WHO or national health authorities. The last reported case was in Saudi Arabia, with date of onset on 26 October 2023.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.